Vesugen — a short tripeptide studied for vascular aging, endothelial repair, and geroprotective effects.
Also known as: Lys-Glu-Asp
Vesugen is a synthetic tripeptide composed of three amino acids: lysine, glutamic acid, and aspartic acid (Lys-Glu-Asp). It belongs to a family of short regulatory peptides developed in Russian gerontology research, designed around the idea that very small peptide fragments can act as targeted signaling molecules — slipping into cells and influencing how specific genes are expressed.
The peptide is studied primarily for its effects on the vascular system. As blood vessels age, the endothelial cells lining them become less able to divide and renew themselves, which contributes to the stiffening and dysfunction associated with cardiovascular aging. Vesugen appears to push back against this process by stimulating endothelial cell proliferation and supporting tissue renewal in aged systems specifically.
What makes Vesugen interesting among peptides is the proposed mechanism: rather than acting as a hormone or growth factor, it appears to work epigenetically — binding directly to the promoter region of genes involved in cell proliferation and effectively turning up their expression where it has dropped off with age.
1 vendor carries Vesugen.
Compare prices →The most direct evidence for Vesugen's vascular effects comes from work on endothelial cell cultures. In studies comparing tissue from young and aged sources, Vesugen stimulated expression of Ki-67, a protein that marks cells actively preparing to divide (2). Ki-67 levels normally fall with age, which is part of why aged endothelium loses its capacity to repair and renew. Restoring this signal is considered one of the more promising routes to reversing vascular aging at the cellular level.
Molecular docking analyses suggest the mechanism is unusually direct. Vesugen appears to physically interact with the promoter region of the MKI67 gene — the stretch of DNA that controls how often Ki-67 is produced (2). The peptide makes contact with a specific sequence located just upstream of where transcription begins, suggesting it functions as an epigenetic regulator that turns gene expression up by binding DNA itself. This kind of small-peptide-to-DNA interaction is what researchers in this field propose as the basis for Vesugen's tissue-specific vasoprotective effects observed in older adults.
Beyond endothelial tissue, Vesugen has been studied for broader geroprotective effects — slowing markers of biological aging at the cellular level. In fibroblast cultures, Vesugen tissue-specifically stimulated expression of CXCL12 and WEGC1, two factors involved in keeping cells properly differentiated and functional (3). The effect was notably stronger in late-passage (aged) cultures than in young ones, which is the pattern researchers look for in a candidate geroprotector: stronger correction where more correction is needed.
A clinical study in adults aged 41–83 with chronic polymorbidity and organic brain syndrome in remission examined Vesugen alongside the related peptide Pinealon (1). Vesugen produced a significant anabolic effect, improved central nervous system and organ activity, and slowed indicators of biological age more visibly than Pinealon. The authors noted some prooxidant signaling and a reduction in CD34+ hematopoietic precursor cells in circulation, suggesting the peptide's effects are not uniformly stimulatory across all cell populations. Importantly, Vesugen did not affect chromatin condensation, indicating it does not appear to disturb genomic stability at the level tested.
In addition to proliferation effects, Vesugen has been examined for how it affects cells under stress. In laboratory tests, Vesugen did not show direct antioxidant activity — it doesn't neutralize free radicals on its own — but it did limit lipid peroxidation in human lipoproteins by modifying their structure, and it increased the stability of red blood cell membranes against osmotic stress (4). In neuronal cultures, it reduced the percentage of dead cells, suggesting a role in regulating the balance between cell survival and programmed cell death.
Vesugen has also been tested in hypoxia models, where short peptides as a class showed protective effects against low-oxygen stress (6). In organotypic pineal tissue cultures, Vesugen did not influence immune cell differentiation but enhanced the proliferation potential of those cells (5) — consistent with the broader theme across the research: Vesugen appears to be a proliferation and renewal signal rather than a differentiation cue, and its effects are most visible in tissue that has lost capacity through aging.
Reported side effects in the published Vesugen research are minimal. No significant adverse effects have been documented in the small clinical and laboratory studies available. One clinical study did note some prooxidant signaling and a reduction in circulating CD34+ hematopoietic precursor cells, suggesting the peptide's effects vary across cell populations and warrant attention in longer-term use (1). Vesugen did not affect chromatin condensation in the tissues examined, which the authors interpreted as a sign of safety at the genetic level (1).
Long-term safety in humans has not been formally characterized, as the larger trials needed to do so have not been completed. The body of Vesugen evidence comes primarily from preclinical and laboratory work, with limited human clinical data so far.
All information on this site is for research and educational purposes only. The compounds discussed are not approved by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.